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Abstract
Whipple’s disease (WD) is a chronic infection caused by Tropheryma whipplei. A 1-
year treatment of oral trimethoprim/sulphamethoxazole (SXT) is commonly used. 
Advances in the culture of T. whipplei has allowed for full genome sequencing and 
antibiotic susceptibility testing, which has demonstrated resistance of T. whipplei to 
trimethoprim. Several mutations in the folP gene that encodes dihydropteroate 
synthase, the target of sulphonamides, has been reported for one patient with 
clinically acquired resistance to SXT. Here we report three new patients who 
experienced clinically acquired resistance to SXT during treatment and one patient 
with biological failure. Sixty-two folP sequences from DNA samples of 59 WD 
patients were also obtained. Among the detected amino acid changes, two positions 
(N4S and S234F) significantly predicted secondary sulphamethoxazole failure (four 
of five). We suggest that these mutations should be detected at the time of WD
diagnosis by sequencing folP in order to avoid sulphamethoxazole monotherapy.
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1. Introduction
Whipple’s disease (WD) is a chronic infection caused by the bacterium Tropheryma 
whipplei, which was fatal before the advent of antibiotics [1]. Since 1952 and the first 
successful use of chloramphenicol, treatment has been empirical until the possible 
determination of antibiotic susceptibilities [1]. In 1966, Ruffin et al. [2] proposed a 
therapy based on penicillin and streptomycin administered parentally for 2 weeks, 
named induction therapy, followed by tetracycline orally for 3–12 months. Physicians 
then described patients who responded to numerous antibiotics, including 
tetracyclines, chloramphenicol, penicillin, streptomycin and 
trimethoprim/sulphamethoxazole (SXT). For many years, tetracycline was the drug of 
choice for maintenance therapy. In 1985, a study revealed a relapse rate as high as 
35% among tetracycline-treated patients, with a high rate of central nervous system 
(CNS) relapse [3]. Induction treatment of parenteral streptomycin together with 
penicillin G for 2 weeks, followed by maintenance therapy of oral SXT [160 mg 
trimethoprim (TMP) and 800 mg (SMX) sulphamethoxazole] twice daily for 1 year 
was then proposed as a ‘reasonable compromise’ [4].
Currently, there is lack of an accurate definition of treatment failure because of 
misinterpretation of previous studies as well as a lack of follow-up to evaluate 
relapses. Primary failure after initiation of adequate WD therapy should be 
differentiated from relapse after antibiotic cessation (Fig. 1). Primary failure includes 
immediate failure observed <3 months after initiation of antibiotics and late failure 
observed >3 months after initiation of antibiotics. Immediate failure includes either a 
lack of amelioration, mainly described in patients with initial neurological involvement 
and treated with tetracyclines, and symptom exacerbation, which may be observed 
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during leprosy during lepromatous reactions or in immune reconstitution [5,6]. Such 
immediate failures may not be due to antibiotic failure or resistance. Late failure 
corresponds with acquired resistance to the treatment and is mainly described for 
SXT [7,8].
Owing to recent success in T. whipplei culture methods, susceptibility tests and full 
genome sequencing have been achieved. Many antibiotics, including doxycycline 
and SXT, are active in vitro [1]. Ceftriaxone and levofloxacin are active in axenic 
cultures, but cephalosporins (including ceftriaxone) and fluoroquinolones are not 
active in cell cultures. Genomic analysis indicates that T. whipplei lacks the coding 
sequence for dihydrofolate reductase, which is a target of TMP [5]. In vitro tests 
confirm that TMP is not active, whereas sulphonamide compounds, such as SMX
and sulfadiazine, exhibit activity [5]. Current recommendations for WD treatment 
involve sulphonamide monotherapy. Recently, we reported mutations in the target 
gene of SMX, folP, that lead to in vitro resistance and secondary clinical failure [8]. 
Herein, we report three new patients with secondary clinical failure in response to 
SXT, one patient who developed biological failure as well as 62 complete sequences 
of folP from 59 patients.
2. Patients, materials and methods
2.1. Patient recruitment
Samples were sent from all over Europe for WD diagnosis [9]. Every time a result 
was consistent with WD, the physicians were asked to provide more data.
Page 5 of 26
Ac
ce
pte
d M
an
us
cri
pt
5
2.2. Definition of acquired resistance
Clinically acquired resistance to SXT is defined by the presence of two conditions: (i) 
an initial clinical response to oral SXT using the adequate dose (320 mg TMP/1600 
mg SMX per day) described in the literature, with complete disappearance of clinical 
signs; and (ii) recurrence of the clinical symptoms observed at the time of WD 
diagnosis under the same treatment with SXT.
Biologically acquired resistance to SXT is defined by the presence of two conditions: 
(i) an initial clinical and biological response to oral SXT using the adequate dose, with 
complete disappearance of clinical signs and negative polymerase chain reaction 
(PCR) analysis; and (ii) reappearance of a positive PCR test under the same 
treatment with SXT.
2.3. PCR amplification and sequencing
Primers used to amplify and sequence folP, the gene encoding dihydropteroate 
synthase (DHPS), the target of SMX, and designed as described previously [8], are 
shown in Supplementary Table 1. The nucleotide and amino acid sequences 
obtained were compared as previously reported [8].
2.4. Statistical analysis
Statistical analyses were performed using Epi Info 6.0 software 
(http://www.cdc.gov/epiinfo/Epi6/EI6dnjp.htm). Differences were considered 
statistically significant at a P-value of <0.05.
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3. Results
3.1. Clinical reports
Four of 44 patients from the database treated with SXT based on current 
recommendations developed clinically acquired resistance to SXT, and one patient 
presented a reappearance of a positive PCR in cerebrospinal fluid (CSF) (5/44;
11.4%).
3.1.1. Patient 1
A 78-year-old man was diagnosed with WD in 2003 [8]. Treatment with SXT resulted 
in the disappearance of manifestations. However, despite continual treatment, 
diarrhoea recurred 19 months later. Tropheryma whipplei PCR, performed as 
previously reported [9,10], was positive in duodenal tissue, saliva, stools, blood and 
CSF. Treatment with doxycycline (200 mg/day) and hydroxychloroquine [200 mg 
three times per day (tds)] was initiated. The patient quickly improved. Twenty-four 
months later, all the T. whipplei PCRs were negative. Periodic acid–Schiff (PAS)
staining and specific immunohistochemistry, performed as previously reported [11],
were slightly positive for duodenal biopsies. The patient is currently undergoing 
therapy. Mutations in the target gene of SMX have been previously detected in this 
patient [8].
3.1.2. Patient 2
A 71-year-old man was diagnosed with WD in 2001 based on weight loss, anorexia, 
asthenia, uveitis, positive PAS staining of duodenal biopsies and vitreous humour, 
and positive specific immunohistochemistry for duodenal biopsies, the vitreous 
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humour and blood samples. The patient was treated with SXT. Significant clinical 
improvement was initially observed. In March 2003 the patient began to present 
clinical manifestations, including asthenia, nausea, ataxia and oculofacial 
myorhythmia. The same treatment was administered. In January 2006, despite SXT 
treatment, the patient exhibited anorexia, weight loss and asthenia. Tropheryma
whipplei PCR was positive for CSF and negative for blood. Doxycycline (200 mg/day) 
and hydroxychloroquine (200 mg tds) treatment was initiated. The patient presented 
significant clinical improvement. Eighteen months later, T. whipplei PCRs of saliva, 
stools, blood, CSF and duodenal biopsies were negative. PAS staining and specific 
immunohistochemistry were slightly positive for duodenal biopsies. The patient felt 
well and is still undergoing treatment.
3.1.3. Patient 3
A 70-year-old man was hospitalised in 2003 for fever, diarrhoea, weight loss and 
anaemia. WD was diagnosed in 1997 by positive PAS staining of duodenal biopsies. 
The patient was treated with SXT for 1 year. All symptoms disappeared. At the time 
of relapse, SXT treatment was started but did not lead to clinical improvement. PAS
staining and specific immunohistochemistry were positive for duodenal biopsies. 
Tropheryma whipplei PCR was positive for duodenal biopsies and stool. Treatment 
comprised of doxycycline (200 mg/day), hydroxychloroquine (200 mg tds) and 
ceftriaxone (2 g/day) was initiated. Rapid improvement was observed. Ceftriaxone 
administration was then immediately stopped. The patient was treated for 20 months. 
Currently, 31 months after the end of treatment, the patient is doing well. Tropheryma
whipplei PCRs of saliva, stools and blood are still negative.
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3.1.4. Patient 4
A 61-year old man was diagnosed with WD in 2005 based on arthralgia, diarrhoea, 
weight loss and positive PAS staining of duodenal biopsies. Rapid disappearance of 
all symptoms was observed after starting SXT; however, after 10 months the patient 
presented new episodes of diarrhoea. Duodenal biopsies were still positive using 
PAS staining and specific immunohistochemistry. Tropheryma whipplei PCR was 
positive for duodenal biopsies and stool, and negative for saliva and CSF. Treatment 
consisting of doxycycline (200 mg/day) and hydroxychloroquine (200 mg tds) was 
initiated and rapid improvement was observed. After 19 months of treatment the 
patient remains well and is still receiving treatment.
3.1.5. Patient 5
A 62-year-old man was diagnosed with intestinal WD since 1985 on the basis of 
positive PAS staining of duodenal biopsies, which was first treated with SXT. In 2003 
he had severe cognitive slowness and gait ataxia and was subsequently diagnosed 
with cerebral involvement of WD on the basis of a positive CSF T. whipplei PCR. He 
was treated with a 4-week course of intravenous ceftriaxone. He showed excellent 
recovery afterwards and had a negative PCR in the CSF. In 2004 he relapsed with 
headache, cognitive slowness on neuropsychological testing and positive CSF T. 
whipplei PCR. Subsequently, he was treated with SXT, again with excellent clinical 
recovery and negative CSF PCR. He continued with SXT afterwards. However, due 
to liver problems, SXT was brought down to half doses in 2007. Six months later he 
had another relapse with headache, subjective cognitive slowness and positive CSF 
T. whipplei PCR. He was treated with ceftriaxone (2 weeks) followed by SXT (320 mg
TMP/1600 mg SMX per day). The symptoms disappeared, but T. whipplei PCRs 
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remained positive 6 months after ceftriaxone treatment, and CSF pleocytosis 
increased under SXT maintenance therapy.
3.2. PCR amplification and sequencing
Forty-one new amino acid folP sequences from 39 patients with T. whipplei infections 
have been obtained since our first report [8]. Among these 39 patients, 3 presented 
secondary clinical failure with SXT and one presented biological failure with the 
reappearance of positive T. whipplei PCR of CSF with SXT. For two of those patients 
with clinical failure, samples were available before and after clinical failure. For the 
third, a sample was available only after clinical failure. For the patient who presented 
a reappearance of positive PCR on CSF, only the specimen sampled after the 
biological failure was available. For the remaining 35 patients, they were either not 
treated with SXT at the time of sampling or information pertaining to therapy or 
follow-up were not known. Twenty-one amino acid sequences of DHPS previously 
described by Bakkali et al. [8] were added for comparison, including two from a 
patient with clinical failure during treatment with SXT and nineteen from laboratory 
strains from patients without any evidence of clinical failure or relapse.
Overall, 62 sequences from 59 patients were analysed. Patient details are 
summarised in Supplementary Table 2. Eight different amino acid sequence types 
were found and specific amino acid substitutions in the DHPS protein are shown in 
Tables 1 and 2. Amino acid sequences for all patients and samples before treatment 
are given in Table 1. Among the amino acid changes present at the time of 
diagnosis, two positions, i.e. N4S and S234F, were significantly associated with 
patients with failure. The N4S change was detected in 3 of 4 patients with failure and 
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in 3 of 54 patients without evidence of failure or without follow-up; this difference was 
significant (P = 0.0003). Moreover, the sensitivity of the N4S substitution to predict 
resistance before treatment was 50%, with 98% specificity, a positive predictive value 
(PPV) of 75% and a negative predictive value (NPV) of 94.4%. The S234F mutation 
was detected in 2 of 4 patients with failure and in 1 of 54 patients without evidence of 
failure or without follow-up; this difference was also significant (P = 0.0024). The 
sensitivity of the S234F change to predict failure before treatment was 66.7%, with a 
specificity of 96.4%, PPV of 50% and a NPV of 98.2%. If we focus on the sequences 
from patients at the time of failure, four (80%) of five presented a signature amino 
acid sequence with either N4S or S234F mutations (Table 2). Moreover, new 
mutations appeared in two out of three amino acid sequences with previous N4S or 
S234F changes.
4. Discussion
The literature is confusing with regard to evaluating WD treatment. Such confusion is 
mainly linked to the fact that current recommendations are considered established 
facts, although they are still based on successive deductive opinions. A lack of an 
accurate definition of treatment failure led to misinterpretation of previous studies. 
Follow-up was often too short to analyse relapses occurrence. Overall, 9.1% of our 
patients treated with SXT relapsed clinically during treatment. To the best of our 
knowledge, only three patients who experienced apparent acquired resistance 
clinically using SXT have been previously reported in the literature [6,7,12]. 
Moreover, data analysis on relapses of patients treated with SXT from several 
studies shows a low rate of 3%, which is probably grossly underestimated [3,6,13].
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Recently, from data of the Study for the Initial treatment of Morbus Whipple (SIMW)
among 40 WD patients treated with SXT (320 mg TMP/1600 mg SMX per day) over 
1 year following a previous treatment with either 2 g ceftriaxone or three doses of 1 g 
meropenem each for 14 days intravenously, there was no relapse 3 years after 
completion of treatment [14]. However, since these data have not been published as 
a full manuscript but only as an abstract form, more comprehensive information 
regarding patients and methodologies is needed.
SXT was selected as a first-line regimen owing to the occurrence of neurological 
relapse in WD and the superior penetration of this compound into the CSF [3,6]. 
However, after excluding patients diagnosed with initial neurological involvement, the 
failure rate was the same in patients treated with tetracyclines or SXT [6]. In addition, 
when considering patients who initially presented with a CNS infection, conflicting 
results were observed. One study suggested that SXT was better than tetracyclines 
[6]. Another reported that 12 patients (40%) treated with SXT did not respond, clearly 
showing that this drug did not efficiently prevent neurological involvement [12].
Currently, SXT is a sulphonamide monotherapy in WD. As for WD, sulphonamides
were shown early in the 20th century to be prone to rapid development of resistance 
[15]. Clinical failure, in vitro resistance to SMX and mutations of DHPS have been 
previously reported in a patient [8]. Herein, we show that the presence of two 
changes in the amino acid sequences of DHPS (N4S and/or S234F) detected at the 
time of diagnosis significantly predicted secondary clinical failure. Besides, new 
amino acid mutations appeared after treatment with SXT in sequences with previous 
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changes at the time of the diagnosis. The risk of resistance appears to be high with 
SMX monotherapy in patients with these mutations.
At the time of WD diagnosis, we suggest that the folP gene must be amplified and 
sequenced from a specimen positive for T. whipplei by PCR in order to detect the 
presence of mutations. This strategy may allow the early detection of resistance or 
the risk to develop resistance to sulphonamide drugs.
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Fig. 1. Schematic representation of failures and relapses in Tropheryma whipplei
infections.
Page 16 of 26
Ac
ce
pte
d M
an
us
cri
pt
1
Table 1
Amino acid sequences of dihydropteroate synthase (DHPS) from 58 samples obtained from 58 patients at the time of diagnosis with 
Tropheryma whipplei infection but before treatment
Patient Code Sample Outcome Amino acid sequences of DHPS
4 42 57 102 162 203 225 232 234 246
1 FrDDbBTF1 DNA from Patient 1 Failure S T V T L N S N S N
2 FrDAhBTF2 DNA from Patient 2 Failure S T V T L N S D F N
3 FrDStATF3 DNA from Patient 3 a Failure N T V T L N S D S N
4 ItDDbBTF4 DNA from Patient 4 Failure S T V T L N S D F N
5 FrDAdp DNA Other N T V T L N S D S N
6 FrDBl1 DNA Other N T V T L N S D S N
7 FrDBl2 DNA Other N T V T L N S D S N
8 FrDBl3 DNA Other N T V T L N S D S N
9 FrDCsf DNA Other N T V T L N S D S N
10 FrDDb1 DNA Other N T V T L N S D S N
11 FrDDb2 DNA Other N T V T L N S D S N
12 FrDDb3 DNA Other N T V T L N S D S N
13 FrDDb4 DNA Other N T V T L N S D S N
14 FrDDb5 DNA Other S T V T L S S N S N
15 FrDDb6 DNA Other N T V T L N S D S N
Edited Table 1
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16 FrDDb7 DNA Other N T V T L N S D S N
17 FrDDb8 DNA Other N T V T L N S D S N
18 FrDDb9 DNA Other N T V T L N S D S N
19 FrDDb10 DNA Other N T V T L N S D S N
20 FrDGb1 DNA Other S T V T L N S D F N
21 FrDGb2 DNA Other N T V T L N S D S N
22 FrDMus1 DNA Other N T V T L N S D S N
23 FrDMus2 DNA Other N T V T L N S D S N
24 FrDSal1 DNA Other N T V T L N S D S N
25 FrDSal2 DNA Other N T V T L N S D S N
26 FrDSal3 DNA Other N T V T L N S D S N
27 FrDSal4 DNA Other N T V T L N S D S N
28 FrDSt1 DNA Other N T V T L N S D S N
29 FrDSt2 DNA Other N T V T L N S D S N
30 FrDSt3 DNA Other N T V T L N S D S N
31 FrECv DNA Other N T V T L N S D S N
32 FrPPb DNA Other N T V T L N S D S N
33 FrUAh DNA Other N T V T L N S D S N
34 ItDSt DNA Other S A V T L S S D S N
35 ItDCsf DNA Other N T V T L N C D S N
36 PortDDb DNA Other N T V T L N S D S I
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37 PortECv DNA Other N T V T L N S D S N
38 SwitECv DNA Other N T V T L N S D S N
39 TunDGb DNA Other N T V T L N S D S N
40 TWIST Strain Other N T V T L N S D S N
41 ENDO 5 Strain Other N T V T L N S D S N
42 NEURO 2 Strain Other N T V T L N S D S N
43 DIG 7 Strain Other N T V T L N S D S N
44 DIG 15 Strain Other N T V T L N S D S N
45 SLOW 1B Strain Other N T V T L N S D S N
46 NEURO 1 Strain Other N T V T L N S D S N
47 ENDO 7Bb Strain Other N T V T L N S D S N
48 DIG 9 Strain Other N T V T L N S D S N
49 DIG 10 Strain Other N T V T L N S D S N
50 DIG ADP 11 Strain Other N T V T L N S D S N
51 ART 1 Strain Other N T V T L N S D S N
52 DIG-NEURO 14 Strain Other N T V T L N S D S N
53 DIG ADP 16 Strain Other N T V T L N S D S N
54 DIG NEURO 18 Strain Other N T V T L N S D S N
55 ENDO 19 Strain Other N T V T L N S D S N
56 NEURO 21 Strain Other N T V T L N S D S N
57 DIG NEURO 23 Strain Other N T V T L N S D S N
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58 TW08-27 Strain Other N T V T L N S D S N
Fr, France; It, Italy; Port, Portugal; Swit, Switzerland; Tun, Tunisia; D, digestive Whipple’s disease; E, endocarditis due to T. 
whipplei; P, pulmonary infection due to T. whipplei; U, uveitis due to T. whipplei; Db, duodenal biopsy; Ah, aqueous humour; St, 
stool; Adp, adenopathy; Bl, blood; Csf, cerebrospinal fluid; Gb, gastric biopsy; Mus, muscle; Sal, saliva; Cv, cardiac valve; Pb, 
pulmonary biopsy; BTF, before treatment failure; ATF, after treatment failure.
a No DNA from specimens sampled before the start of treatment was available for this patient. Thus, the amino acid sequence used 
in this table was obtained at the time of clinical failure. Indeed, we can suspect that both sequences (before and after failure) are the 
same as no mutation was detected in the sequence obtained at the time of the failure.
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Table 2
Amino acid sequences of dihydropteroate synthase (DHPS) obtained from eight 
samples from five patients, including four patients with acquired clinical resistance 
(Patients 1, 2, 3 and 4) and one patient who presented reappearance of a positive 
polymerase chain reaction (PCR) from cerebrospinal fluid
Patient Code Sample Amino acid sequences of DHPS
4 42 57 102 162 203 225 232 234 246
1 FrDDbBTF1 DNA S T V T L N S N S N
FrDDbATF1 DNA S T I P I N S N S N
2 FrDAhBTF2 DNA S T V T L N S D F N
FrDCsfATF2 DNA S T V T L S S D F N
3 FrDStATF3 DNA N T V T L N S D S N
4 ItDDbBTF4 DNA S T V T L N S D F N
ItDDbATF4 DNA S T V T L N S D F N
5 NetDCsfATF DNA S T V T L N S D F N
Fr, France; It, Italy; Net, Netherlands; D, digestive Whipple’s disease; Db, duodenal 
biopsy; Ah, aqueous humor; Csf, cerebrospinal fluid; St, stool; BTF, before treatment 
failure; ATF, after treatment failure.
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Start antibiotic treatment Stop antibiotic treatment Follow-up
Immediate failure Late failure Relapse
mainly cerebral
(eventually very late relapse)
Worsening Lack of amelioration Mainly with trimethoprim/sulphamethoxazole
(acquired resistance)
Immune Reported cases with tetracyclines
reconstitution in patients with initial neurological involvement
Edited Figure 1
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Supplementary Table 1
Primers used in this study to frame and amplify the folP sequences
Primer Sequence
FolpF1 5’-ACC-TGC-ATT-TTG-GAT-GAA-GC-3’
FolpR1 5’-TAA-TGG-CAA-CAC-CCA-TGC-TA-3’
FolpF2 5’-CCC-ATT-TCC-ACC-TCC-TAA-TG-3’
FolpR2 5’-CGG-CAG-TAA-TAC-GCT-CGA-TA-3’
FolpF3 5’-GCC-TTG-CTC-ATT-ACG-ACG-AT-3’
FolpR3 5’-GTG-TGA-GCT-GAG-GCA-ACA-TC-3’
Edited Supplementary Table 1
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Supplementary Table 2
Details of the 59 patients included in the study
Patient code Sex/age
(years)
Main manifestations a Main samples tested positive for Tropheryma
whipplei b
FrDDbBTF1 M/78 A, diarrhoea Db, Sal, St, Bl, Csf
FrDAhBTF2 M/71 WL, uveitis Db, Bl, Ah, Csf
FrDStATF3 M/70 Diarrhoea, WL, fever Db, St
ItDDbBTF4 M/61 A, diarrhoea, WL Db, St
NetDCsfATF M/62 Diarrhoea, neurological signs Db, CSF
FrDAdp F/57 A, WL, Adp, neurological signs Db, Sal, St, Bl, Adp, Csf
FrDBl1 M/42 A, diarrhoea Db, Sal, Bl
FrDBl2 M/60 A, diarrhoea, WL, AP, fever Db, Bl
FrDBl3 M/58 A, diarrhoea, WL, AP, fever Db, Bl
FrDCsf F/57 A, Adp Db, Adp
FrDDb1 F/58 A Db, St, Bl
FrDDb2 M/77 Diarrhoea, Adp Db, Adp
FrDDb3 M/66 Diarrhoea Db, Sal, Bl
FrDDb4 M/46 A, fever Db, Csf
FrDDb5 M/58 A, diarrhoea Db, Sal, St
FrDDb6 M/60 A, WL, fever, Adp Db, Sal, St
FrDDb7 M/35 A, WL, fever Db
Edited Supplementary Table 2
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FrDDb8 F/69 A Db
FrDDb9 M/56 A, diarrhoea Db, Sal, St, Bl
FrDDb10 M/46 A Db, Sal, Bl
FrDGb1 M/50 Diarrhoea Db
FrDGb2 M/60 A, diarrhoea, Adp Db, Sal, St, Bl
FrDMus1 F/73 A, WL, myalgia, Adp Db, Sal
FrDMus2 M/67 A, fever, myalgia Db, Bl
FrDSal1 F/71 Diarrhoea, WL, headache Db, Sal, St
FrDSal2 M/74 A, diarrhoea, Adp Db
FrDSal3 M/42 A, diarrhoea Db, Sal, St, Csf
FrDSal4 M/43 A, diarrhoea, neurological signs Db, Sal, Bl, Csf
FrDSt1 F/40 A, Adp, fever Db, Sal, St, Bl
FrDSt2 M/40 A, diarrhoea, WL, AP, Adp, fever Db, Sal, St
FrDSt3 M/50 A, diarrhoea, WL, AP Db
FrECv M/57 A, WL, fever, endocarditis, neurological
signs
Db, Sal, St, Cv
FrPPb F/55 Pulmonary signs Sal, St, lung biopsy
FrUAh F/78 Uveitis Ah
ItDSt M/NA Diarrhoea Db, St
ItDCsf M/58 Diarrhoea, neurological signs Db, Csf
PortDDb M/50 Fever Db, Sal, St
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PortECv M/58 Endocarditis Cv
SwitECv M/75 Endocarditis Cv
TunDGb M/NA NA Db
TWIST M/42 Endocarditis Cv
ENDO 5 M/61 Endocarditis Bl, Cv
NEURO 2 F/40 A, neurological signs Db, Sal, St, Csf
DIG 7 M/64 A, WL Db, Sal, St, Bl
DIG 15 M/60 A, diarrhoea, WL, fever Db, Csf
SLOW 1B F/34 WL, AP Db, St
NEURO 1 M/57 Diarrhoea, WL, neurological signs Db, Csf
ENDO 7Bb M/67 Endocarditis Bl, Cv
DIG 9 M/35 A, diarrhoea, WL, fever, Adp Db, Sal, St, Bl
DIG 10 M/46 A, diarrhoea, WL, neurological signs Db, Csf, Adp
DIG ADP 11 M/56 Diarrhoea, WL Db, St, Adp
ART 1 M/68 A Db, Sf
DIG-NEURO 
14
M/50 NA Db, Csf
DIG ADP 16 F/38 A, diarrhoea, WL, AP, Adp Db, Bl, Adp
DIG NEURO 
18
M/68 A, Adp, fever, neurological signs Db, St, Csf
ENDO 19 M/NA Endocarditis Cv
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NEURO 21 M/57 Diarrhoea, pigmentation Db, Csf
DIG NEURO 
23
F/57 A, diarrhoea, AP, Adp, fever Db, Sal, St, Csf
TW08-27 F/NA NA Csf
a A, arthralgia; WL, weight loss; Adp, adenopathy; AP, abdominal pain; NA, not available.
b Db, duodenal biopsy; Sal, saliva; St, stools; Bl, blood; Csf, cerebrospinal fluid; Ah, aqueous humour; Adp, adenopathy; Cv, cardiac 
valve; Sf, synovial fluid.
